Market watchers align mdcx stock price forecast revisions with broader healthcare sector rallies. Monthly RSI readings now hover near 58, indicating room for upside before overbought conditions. Things are changing fast in the stock market, but we're staying focused on the future. Worried about the market? We're doubling down on this stock . The purpose of the Type C meeting is to formally discuss the D-MNA product development and gain further alignment on the clinical pathway. The Company's aim is to gain the FDA's consent to fast-track the clinical development program and seek feedback on future clinical plans for the D-MNA development program. More specifically, a list of draft questions and key topics seeking the FDA's feedback are: Recent mdcx trading has outperformed similar microcap healthcare peers. Price forecast models anticipate a $9.20 target by mid-August if institutional buying patterns persist.